ReLive is spearheading regenerative cell therapies to address unmet needs in the areas of orthopedic sports medicine and plastic surgery.
ReLive Biotechnologies LTD has raised $43.0M in total funding. The most recent round was Series A. The last funding was announced in January 2023.
ReLive Biotechnologies LTD's investors include Shanghai Healthcare Capital, Indaco Capital, Jiuyou Capital.
ReLive Biotechnologies LTD is headquartered in Newton, United States.
ReLive is spearheading regenerative cell therapies to address unmet needs in the areas of orthopedic sports medicine and plastic surgery.
ReLive Biotechnologies LTD is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ReLive Biotechnologies LTD — Funding & Investors." VCBacked, January 16, 2023, https://www.vcbacked.co/company/relive-biotechnologies-ltd. Accessed August 13, 2026.
VCBacked. (2023). ReLive Biotechnologies LTD — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/relive-biotechnologies-ltd
{{cite web |title=ReLive Biotechnologies LTD — Funding & Investors |url=https://www.vcbacked.co/company/relive-biotechnologies-ltd |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated